AETHERA
In AETHERA, a year of the CD30 ADC after transplant halved relapse risk in high-risk patients.
PFS HR 0.57 (median 42.9 vs 24.1 months); no OS difference (crossover). Approved August 2015 as post-transplant consolidation.
Setting
High-risk Hodgkin lymphoma after autologous transplant: brentuximab vedotin consolidation vs placebo
Phase
Phase 3
Sponsor
Seagen
Registry
Headline result
PFS HR 0.57.
Reported
2015
Enrolled
329
In plain words
What these results mean for people, not percentages
Progression-free survival (median)primarysurrogate endpoint
- Median 42.9 vs 24.1 months with Brentuximab vedotin compared with Placebo; about 18.8 months longer for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 43 percent lower chance of the event at any given time (hazard ratio 0.57, likely range 0.4 to 0.81).
- This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
- These results apply to the people the trial enrolled: High-risk Hodgkin lymphoma after autologous transplant: brentuximab vedotin consolidation vs placebo. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.